BIBW 2992

afatinib · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

13 regulatory and trial events tracked for BIBW 2992, covering 2013-11-19 to 2024-02-06. Get the full timeline:

Most recent: Clinical Trial Update: Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer [Phase 2]